Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Edwards Lifesciences (EW)

NYSE: EW · Medical Devices · Irvine, CA

Our rating: Neutral

Neutral reaffirmed at $100.82, moderate conviction, November 5, 2026.

Breaks if: The neutral call moves cautious if revenue growth decelerates below 8% year-over-year in two consecutive quarterly reports — at that pace, 55x earnings becomes indefensible regardless of franchise quality. It moves positive if revenue growth reaccelerates to 14% or above for two consecutive quarters and operating margins expand, suggesting the premium multiple is earnable. Neither condition is true at today's reported figures.

Key figures

Market value$58.6B
Revenue, last 12 months$6.7B
Net income, last 12 months$1.0B
Free cash flow, last 12 months$1.4B
Price to earnings57.3×
Free cash flow yield2.4%
Dividend yield0.0%
Operating margin21.6%
Return on equity9.7%
Beta to the S&P 5000.55
Volatility, annualized31.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.7B10.5%$0.53$507M
June 30, 2026$1.7B13.6%$0.42$585M
March 31, 2026$1.6B16.7%$0.66−$21M
December 31, 2025$1.6B13.3%$0.16$354M
September 30, 2025$1.6B14.7%$0.50$516M
June 30, 2025$1.5B11.9%$0.56$241M
March 31, 2025$1.4B6.2%$0.61$224M
December 31, 2024$1.4B9.4%$0.65−$177M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 16 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.